Innovative drugs for myasthenia gravis have been launched domestically, injecting strength into the lives of rare disease patients
2023-09-05
One portion of steamed eggs, one portion of water tofu, some soaked until soft and rotten soybeans and vegetable stems. Before the press conference, a set of long-term medical records for patients with myasthenia gravis (MG) was placed on each seat, allowing people to slightly "taste" the taste of suffering from this rare disease. On the 5th, a press conference was held in Suzhou, Jiangsu Province for the launch of the innovative myasthenia gravis drug Aijiamod (Weiweijia?). On the same day, more than ten provinces and cities across China, including Beijing, Shanghai, Jiangsu, and Jiangxi, issued the first batch of prescriptions, bringing new treatment options for patients with this rare disease. Hu, who is 43 years old this year, comes from Datong, Shanxi Province. He was originally a robust veteran. In March 2020, Brother Hu felt uncomfortable with his eyelids, which began to droop. He had to use one hand to support his eyelids while driving to work. Brother Hu has also sought medical attention from the hospital, but he has never been able to identify any specific symptoms. A year later, the condition became increasingly severe: weak corners of the mouth, making it difficult to smile; Chewing and swallowing are weak, and even my favorite ribs cannot be chewed; Chest tightness and shortness of breath require four or five midway breaks when returning home on the 6th floor. Once, while chatting with family and friends, they mentioned the rare disease of myasthenia gravis, and it was only then that Hu discovered the true culprit of his condition. Myasthenia gravis is a chronic, autoimmune neuromuscular disease caused by dysfunction of nerve muscle junction transmission, characterized by recurrent muscle weakness and susceptibility to fatigue. For patients, smiling, breathing, and swallowing have become extravagant expectations. In the 1993 TV drama 'Passionate', which was once popular, the male protagonist played by Wang Zhiwen suffered from myasthenia gravis in dialect. At present, the annual incidence rate of myasthenia gravis in China is 0.68/100000 people. In 2018, generalized myasthenia gravis (gMG) was included in the "First Batch of Rare Diseases Catalogue" released by the National Health Commission and other departments. According to Li Xiang, Executive Director of Zaiding Medical Affairs Department, the majority of gMG patients have IgG autoantibodies, of which approximately 75% to 80% are acetylcholine receptor (AchR) antibody positive patients. Agamod can clear pathogenic IgG antibodies in the body through its unique mechanism of action, and has outstanding characteristics in terms of onset time, efficacy, and safety. At the end of June this year, Agamod was officially approved for listing by the National Drug Administration. In recent years, with the promotion of the construction of a healthy China, China's attention to rare diseases has also been increasing. As of the end of February this year, 199 rare disease drugs have been launched globally, involving 87 disease types. Among them, 103 drugs are listed in China, involving 47 rare diseases. In 2022, a total of 111 new drugs were added to the national medical insurance drug catalog, and new drugs for rare diseases became the focus of medical insurance negotiations. According to Liang Yi, CEO of Zaiding Pharmaceutical and President of Greater China, there are currently 25 rare disease drugs out of the 2023 National Medical Insurance Drug List that have passed the preliminary review, including "Agamod" α Injection ". Liu Junshuai, Vice Chairman of the Medical Policy Special Committee of the China Association for the Promotion of Pharmaceutical Innovation and a member of the Second Rare Disease Diagnosis, Treatment and Support Expert Committee of the National Health Commission, who attended the press conference, said: "The accessibility of medication largely determines the standardized treatment level and diagnosis and treatment of diseases
Edit：GuoGuo Responsible editor：FangZhiYou
Source：Chinanews.com
Special statement: if the pictures and texts reproduced or quoted on this site infringe your legitimate rights and interests, please contact this site, and this site will correct and delete them in time. For copyright issues and website cooperation, please contact through outlook new era email：lwxsd@liaowanghn.com
Recommended Reading Change it 
Home
